Singular Health Group Limited announced the execution of a Master Distribution Agreement ("MDA") for its 3Dicom software in the United States of America with Charlie Golf One Solutions LLC ("CG1"). Charlie Golf One Solutions was previously appointed as Singular Health's inaugural sales partner in November 2022. Having previously developed, deployed, scaled, and successfully exited augmented reality (AR), virtual reality (VR) and mobile applications in the defence and healthcare markets, CG1 have a proven record in commercialising software applications and have established a large network of partner organizations operating in federal government and commercial sectors.

Since their appointment as a member of Singular Health's Partner Program in November, Singular Health has been working closely with CG1 and their partner organizations to develop an enterprise sales pipeline that encompasses several large-scale, but longer lead- time federal government agency projects and numerous corporate licensing deals, and in the short-to-medium term, enterprise sales to large healthcare institutions in South Florida. Whilst these opportunities continue to progress through the sales process, there has been a general consensus amongst potential purchasers and early-adopters using the software that the cohesive nature of the 3Dicom software suite, which allows the secure, wireless transfer of medical images and 3D visualisation across mobile, desktop, and virtual reality, better facilitates patient education and collaboration. Although these opportunities continue to progress, the Company can not guarantee that any, or all, of these opportunities will materialise, or result in material revenue.

In connection with the MDA, CG1 is appointed as a master distributor of Singular Health's software licences and shall be enabled to appoint their partner organizations as sub- distributors on a commissions-based remuneration structure, providing a substantial in- country sales presence to further progress Singular Health's enterprise sales pipeline. With initial exclusivity over five nominated States (Florida, North Carolina, Georgia, Nevada, and Texas), CG1 has the right to gain exclusivity in continental United States of America based on achieving certain minimum sales targets, based on annual contract value, within set timeframes.